How long does a tirzepatide plateau last?

There is no fixed duration. Research has defined a plateau over repeated 12-week intervals, while a few flat weeks can reflect water, sodium, bowel contents or weighing conditions. If the longer-term average is unchanged, a prescriber can review dose progression, consistency, injection technique, sleep, medications and medical factors before deciding whether the pattern is expected maintenance.

Why did I stop losing weight on tirzepatide?

Weight loss can slow because a smaller body uses less energy and weight reduction increases biological pressure to eat. The medication may still be moderating appetite while those forces reach a new balance. Missed doses, injection technique, food patterns, sleep, weight-promoting medications and conditions such as thyroid disease can also contribute, which is why the full trend deserves clinical review.

Does tirzepatide stop working after a year?

Not necessarily. In SURMOUNT-1, average weight loss slowed over 72 weeks, yet the mean change still reached 15.0% to 20.9% across the three tirzepatide doses. Slower scale movement can occur while the medication continues to affect appetite and supports maintenance of a lower weight. Individual response varies, so a trial average is not a personal target.

Should a tirzepatide dose increase after a plateau?

Only the prescribing clinician can determine whether a dose change is appropriate. The decision depends on where the patient is in titration, current dose, tolerability, adherence, response and health history. A plateau alone does not make escalation automatic, and the highest available dose is not a universal goal. The prescriber sets the actual dose.

Can switching from tirzepatide to semaglutide break a plateau?

There is no good trial evidence that switching to semaglutide reliably breaks a tirzepatide plateau. SURMOUNT-5 compared the two medications from the start; it did not enroll people specifically to test a switch after stalled weight loss. Semaglutide may be considered for individual clinical reasons, but it is a separate treatment decision rather than a proven reset.

Tirzepatide Plateau: Why Weight Loss Slows

A tirzepatide plateau does not automatically mean the medication has stopped working. Weight loss normally slows as body weight falls, energy needs decline and the biological drive to eat grows stronger. The useful question is not whether the scale moved this week. It is whether the trend has been flat long enough to represent a new balance, and whether something correctable—dose progression, missed doses, injection technique, sleep, another medication or a medical condition—is contributing.

What counts as a tirzepatide plateau?

There is no single clinic-wide definition. A fortnight at the same number is usually too short. Water retention, sodium, bowel contents, menstrual-cycle changes and the time of weighing can hide fat loss or create a temporary gain. A four-week rolling average is more informative than comparing two isolated mornings.

A 2025 post-hoc analysis of SURMOUNT-1 and SURMOUNT-4 used a deliberately broad research definition: less than 5% weight change over a 12-week interval and every later 12-week interval. In SURMOUNT-1, median time to that plateau ranged from 24.3 to 36.1 weeks across baseline BMI groups, and 87.6% to 90.2% of participants in those groups had reached one by week 72 (Horn et al., Clinical Obesity 2025). That definition describes a sustained flattening, not an ordinary two-week wobble.

What the tirzepatide trial curve actually shows

SURMOUNT-1 followed 2,539 adults with obesity or overweight without diabetes for 72 weeks. Mean weight change was −15.0% with 5 mg, −19.5% with 10 mg and −20.9% with 15 mg, versus −3.1% with placebo (Jastreboff et al., New England Journal of Medicine 2022). Those are group averages, not targets for an individual.

The curve is steepest early and becomes shallower over time. The trial also included a 20-week escalation period, so early change cannot be compared cleanly with later maintenance. The tirzepatide weight-loss results page shows the full curve; the important point here is its shape. Continued treatment and a slower rate of change can coexist.

Why weight loss slows even when treatment continues

A smaller body generally uses less energy. Beyond that arithmetic, the body can reduce expenditure more than its change in size alone would predict. In a tightly controlled human study, maintaining weight 10% or more below baseline was associated with compensatory reductions in total energy expenditure (Leibel et al., New England Journal of Medicine 1995). This is often called adaptive thermogenesis.

Appetite pressure changes too. A human energy-balance analysis estimated that appetite rose by about 100 calories per day for each kilogram of weight lost—more than three times the estimated expenditure adaptation (Polidori et al., Obesity 2016). That figure did not come from a tirzepatide trial, so it should not be treated as a personal calorie formula. It demonstrates the direction and strength of the biological feedback.

Tirzepatide can weaken that appetite response without erasing it. A 2024 mathematical-modeling study fitted weight trajectories for diet restriction, semaglutide and tirzepatide and found that both medications appeared to weaken appetite feedback and extend weight loss before a plateau (Hall, Obesity 2024). A plateau is where the medication's ongoing effect and the body's counter-pressure reach a new balance.

Would switching to semaglutide reset the curve?

Not predictably. SURMOUNT-5 directly randomized 751 adults with obesity but without diabetes to tirzepatide or semaglutide for 72 weeks; mean loss was 20.2% and 13.7%, respectively (Aronne et al., New England Journal of Medicine 2025). It compared treatments from the start. It did not test semaglutide as a way to break a tirzepatide stall.

Semaglutide remains a related clinical option, but switching is a new treatment decision with its own dose progression and tolerability questions. The broader tirzepatide-versus-semaglutide comparison explains the molecule-level differences.

What a prescriber reviews before calling it failure

A useful review is systematic rather than punitive. It usually covers:

Time and dose. Someone still moving through titration may not yet be at the dose their prescriber intends to maintain. Higher tirzepatide doses were associated with a later plateau in the 2025 post-hoc analysis, but that does not make escalation automatic. The tirzepatide dosage schedule explains how those decisions are made.
Consistency and technique. The provider can check refill gaps, missed injections, storage, pen or syringe use and whether the full prescribed amount was delivered. This is troubleshooting, not a reason to add extra medication.
Food pattern and protein. Appetite suppression can fade in felt intensity, portions can drift and liquid calories are easy to miss. Protein also matters because weight reduction includes some lean tissue; why lean mass matters during GLP-1 weight loss covers that evidence in detail.
Sleep and activity. Short or disrupted sleep can change hunger and daily movement. A smaller body can also make the same routine less energetically demanding than it was at baseline.
Other medications. Some antidepressants, antipsychotics, insulin, sulfonylureas and corticosteroids can promote weight gain. The answer is a medication review, not stopping a prescribed drug without its prescriber.
Medical factors. Thyroid disease, fluid retention, menopause-related changes and worsening diabetes can alter the trend. Symptoms and history determine whether examination or laboratory testing is useful.

A plateau can be the expected end state

Weight management has two phases: reduction and maintenance. Reaching a stable, lower weight can mean treatment has arrived at its sustainable effect, not that the earlier loss was cancelled. Trial averages cannot decide what weight is medically appropriate for one person, and pushing the dose solely to chase a number can add tolerability problems without answering the underlying question.

Whether to adjust the dose, continue into maintenance, or consider another medication is a decision for the patient and prescriber together.

Make the follow-up about the trend

A useful appointment starts with dates: weekly weights under similar conditions, the prescribed dose and when it changed, any missed injections, appetite changes, sleep, activity, new symptoms and a complete medication list. That record gives the prescriber something better than a single scale reading to assess.

At Promise, a licensed provider reviews every request and not everyone qualifies. The provider sets the dose and decides whether continued treatment, a change or a maintenance plan is medically appropriate.

The aim is not to force the original rate of loss to continue forever. It is to determine whether the apparent stall is noise, a correctable treatment issue or the stable lower weight the current plan can support.